Short report

Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus

Changbao Liu, Nicole D Day, Patrick J Branigan, Lester L Gutshall, Robert T Sarisky and Alfred M Del Vecchio*

Address: Centocor R&D, Inc., 145 King of Prussia Road, Radnor, Pennsylvania, 19087, USA

Email: Changbao Liu - Cliu12@cntus.jnj.com; Nicole D Day - NDay2@cntus.jnj.com; Patrick J Branigan - Pbraniga@cntus.jnj.com; Lester L Gutshall - LGutshal@cntus.jnj.com; Robert T Sarisky - RSarisky@cntus.jnj.com; Alfred M Del Vecchio* - Adelvecc@cntus.jnj.com

* Corresponding author

Abstract

To elucidate the relationship between resistance to HRSV neutralizing antibodies directed against the F protein and the fusion activity of the F protein, a recombinant approach was used to generate a panel of mutations in the major antigenic sites of the F protein. These mutant proteins were assayed for neutralizing mAb binding (ch101F, palivizumab, and MAb19), level of expression, post-translational processing, cell surface expression, and fusion activity. Functional analysis of the fusion activity of the panel of mutations revealed that the fusion activity of the F protein is tolerant to multiple changes in the site II and IV/V/VI region in contrast with the somewhat limited spectrum of changes in the F protein identified from the isolation of HRSV neutralizing antibody virus escape mutants. This finding suggests that aspects other than fusion activity may limit the spectrum of changes tolerated within the F protein that are selected for by neutralizing antibodies.

Findings

Human respiratory syncytial virus (HRSV) is the most common cause of serious lower respiratory tract infections in infants and young children worldwide [1]. The F protein represents the major protective antigen conserved between subgroups A and B to which neutralizing antibodies are directed [2-5]. As no vaccines against HRSV are approved, antibody-based prophylaxis with the anti-HRSV F protein antibody palivizumab is the only approved prevention for serious infections in at-risk infants [6,7]. Although resistance to palivizumab currently is not an issue in the clinic [8], wider use of palivizumab may increase this potential. An affinity matured version of palivizumab (motavizumab) is currently in clinical development [9]. Since it is derived from palivizumab, it recognizes a similar epitope [10] thus viral resistance patterns are anticipated to be similar. Palivizumab antibody escape mutants have been studied in vitro and in vivo [11-14]. One of the palivizumab escape mutants (MP4) appears to be more fit in both in vitro and in vivo competitive replication [11], although the reason for this increased fitness is unknown. MAb19 is another murine HRSV neutralizing mAb previously in clinical development [15-17]. Replacement of arginine 429 with serine within antigenic site IV/V/VI confers resistance to MAb19 [15,18]. This antigenic site contains overlapping epitopes as defined by several mAbs [19]. Ch101F is a potent neutralizing antibody generated by grafting the variable regions from murine mAb (101F) onto human IgG1 constant frameworks. By several methods, K433 in antigenic site IV/V/VI was identified as critical for binding [20]. Although mutation of K433 to several residues in recom
binantly expressed F protein prevented ch101F binding, only one change (K433T) was identified by mapping of ch101F escape mutant viruses. The same escape mutation was reported for mAb R7.936/4 [19]. To better understand the relationship between resistance to anti-HRSV F protein antibodies and F protein function, we used a recombinant approach to generate a panel of mutations in antigenic sites II and IV/V/VI [18] of the F protein and characterized these mutations with respect to expression, neutralizing mAb binding, and fusion activity as previously described [21] in an attempt to better understand the mechanism of action of HRSV neutralizing antibodies and the impact of resistance to these antibodies upon the fusion activity of the F protein. A summary of these results is presented in Table 1. The HRSV neutralizing mAbs palivizumab, MAb19, and ch101F were selected for study as these are potent and are either marketed (palivizumab, Synagis®, reviewed in [22]), have been in clinical development (MAb19, RHZ19) [16,17,23], or are good candidates for clinical development (ch101F) [20], respectively. They also recognize one of the two major antigenic sites (site II or site IV/V/VI) within the F protein, and residues in their epitopes critical for binding have been somewhat characterized.

| Mutation | Processing | Percent binding ch101F | Percent binding palivizumab | Percent binding MAb19 | Fusion activity |
|----------|------------|------------------------|----------------------------|----------------------|----------------|
| Wild-type | Complete   | 99.9                   | 100.0                      | 99.9                 | 1.0 ± 0.0     |
| K272M    | Complete   | 126.6                  | 3.8                        | 100.5                | 2.3 ± 0.7     |
| K272N    | Complete   | 95.5                   | 15.3                       | 62.3                 | 2.2 ± 0.5     |
| K272Q    | Complete   | 85.3                   | 30.1                       | 88.7                 | 2.6 ± 0.1     |
| K272T    | Complete   | 70.4                   | 9.1                        | 68.0                 | 1.0 ± 0.1     |
| S275F    | Complete   | 29.4                   | 10.9                       | 31.7                 | 1.6 ± 0.2     |
| T400A    | Complete   | 155.2                  | 126.6                      | 161.2                | 2.9 ± 0.5     |
| C422S    | Complete   | 159.6                  | 177.5                      | 193.9                | 1.6 ± 0.6     |
| N428D    | Complete   | 116.2                  | 139.4                      | 121.3                | 0.75 ± 0.02   |
| N428Q    | Complete   | 117.2                  | 190.2                      | 193.8                | 1.5 ± 0.02    |
| R429K    | Complete   | 44.6                   | 88.8                       | 11.2                 | 4.0 ± 0.2     |
| R429S    | Complete   | 72.5                   | 150.0                      | 3.9                  | 1.1 ± 0.1     |
| G430A    | Complete   | 79.7                   | 166.5                      | 0.15                 | 1.2 ± 0.2     |
| I431A    | Complete   | 61.9                   | 108.2                      | 81.8                 | 1.6 ± 0.3     |
| I431L    | Complete   | 78.5                   | 80.9                       | 65.5                 | 1.8 ± 0.1     |
| I432L    | Complete   | 74.9                   | 68.9                       | 64.4                 | 1.5 ± 0.2     |
| I432Q    | Complete   | 49.3                   | 60.8                       | 57.9                 | 0.7 ± 0.07    |
| I432T    | Complete   | 191.7                  | 206.9                      | 169.8                | 1.4 ± 0.3     |
| K433D    | Complete   | 1.1                    | 29.9                       | 1.6                  | 0.4 ± 0.01    |
| K433L    | Complete   | 3.8                    | 88.1                       | 24.5                 | 0.5 ± 0.1     |
| K433N    | Complete   | 2.9                    | 80.7                       | 28.7                 | 2.2 ± 0.5     |
| K433Q    | Complete   | 2.7                    | 60.7                       | 47.4                 | 1.0 ± 0.8     |
| K433R    | Complete   | -0.6                   | 15.8                       | 23.1                 | 2.0 ± 0.6     |
| K433T    | Complete   | 3.9                    | 64.5                       | 64.4                 | 0.6 ± 0.04    |
| K433S    | Complete   | 69.5                   | 86.3                       | 111.8                | 0.98 ± 0.19   |

Processing is defined as relative amounts of F0, F1, and F2, and is described as being equivalent to wild-type HRSV F protein (complete) or reduced. Reactivity with neutralizing mAbs (palivizumab, Mab19, and ch101F) as determined by flow cytometry is reported as percent relative to wild-type HRSV F protein. Cell fusion activity (luciferase activity) is reported relative to wild-type as described in [30]. All values are expressed as relative to wild-type.
of the F protein, although this mutant was not identified during a selection of MAb19 escape mutants [15].

Previous results had identified K433 as a critical residue for the binding of ch101F. Mutation of K433 to D, L, N, Q, R, or T abolished ch101F binding as previously reported [20], but, with the exception of K433D and K433R, modest to no effects upon palivizumab binding. These mutations also reduced the binding of MAb19 to various degrees highlighting the complexity of antigenic site IV/VI. It is interesting to note that while mutation of K433 to threonine had such a marked effect upon ch101F binding, mutation of K433 to the structurally similar serine had little to no effect. Mutation of K433 either increased fusion activity (K433R, K433N), reduced it by 50% (K433D, K433L, K433T), or had little to no effect (K433Q, K433S). Mutation K433D appeared to reduce binding of all three mAbs suggesting that this mutation was not efficiently expressed on the cell surface as the other mutations, which may account for its reduced fusion activity. Mutations T400A, C422S [21], N428D, and N428Q around the site IV/VI region had no effect upon mAb binding or fusion activity which show this is not a region of F protein hypersensitive to mutations.

The classical approach of selecting antibody escape mutant viruses is limited by the impact of such mutations upon viral growth fitness, and in general, provides a much more limited spectrum of residue changes. Antibody escape mutants selected with ch101F revealed only a single change in lysine residue 433 to threonine suggesting that there are additional constraints on this region of the protein that limit which amino acids changes are tolerated in this region. Furthermore, the only change identified for antibody escape mutant viruses selected with MAb19 was a single change at R429 to S. Interestingly, it appears that resistance to mAbs which map to antigenic site IV/VI requires more passages in vitro for selection [19]; however, the relative fitness of site II and site IV/VI escape mutants would need to be assessed in parallel to determine if this is true. The F protein shows a high degree of conservation both within and between subgroup A and B, as well as with bovine RSV. Given this high degree of conservation, it was somewhat surprising that the functional analysis of the fusion activity of the panel of mutations described here revealed that the fusion activity of the F protein is tolerant to multiple changes in the site II and IV/VI region. These changes included those identified from the selection of mAb escape mutants as well as other residue changes not identified in escape mutants. These results suggest that aspects other than fusion activity may limit the spectrum of changes tolerated within the F protein. Although the F protein is the only virion surface protein required for fusion and viral entry [25-27], the F protein is also essential for the formation of mature virion particles [26,28,29]. It is possible that the RNA sequence of this region contains some critical function, and/or that mutations in this region of the F protein impact some other unknown function(s) essential for virus growth. If these mutation affect the F protein, they would also suggest that antibodies such as MAb19 and ch101F may not neutralize virus solely by inhibition of fusion. Additional studies may provide direct information on the mechanism of action of HRSV neutralizing antibodies directed against the F protein such as ch101F.

A thorough characterization of the epitopes on the F protein for HRSV neutralizing mAbs may provide insights into the mechanisms of action by which mAbs against the HRSV F protein neutralize virus as well as a better understanding of the mechanism by which the F protein mediates cell fusion. Such studies may provide additional insights into the function of the F protein, and help in the selection and development of clinical candidates, such as ch101F, for next generation antibody-based prophylaxis and therapy for HRSV infections.

**Abbreviations**

HRSV Human respiratory syncytial virus

F protein fusion protein

mAb monoclonal antibody

ch101F chimeric 101F

WT wild-type

**Competing interests**

The authors declare that they are employees of Centocor, Inc. which provided support for this work.

**Authors’ contributions**

CL generated reagents and performed the fusion assays. PB and ND performed the flow cytometry. LG conducted sitedirected mutagenesis of the HRSV F protein. AD and RS participated in the design, oversight of the conduct of the experiments, and interpretation of the results. All authors have read and approved the final manuscript.

**Acknowledgements**

We thank Geraldine Taylor and Jose Melero for generously providing mAb19 hybridoma supernatant, and 101F antibody, as well as helpful discussions and comments.

**References**

1. Stensballe LG, Devasundaram JK, Simoes EA: Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. *Pediatr Infect Dis J* 2003, 22:S21-32.
1. Anderson LJ, Bingham P, Hierholzer JC: Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol. 1988, 62:4232-4238.

2. Beeler JA, van Wyke Coelingh K: Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989, 63:2941-2950.

3. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA: Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol. 1989, 63:925-932.

4. Johnson S, Oliver C, Prince GA, Hemming VG, Wang SC, Dormitzer M, O’Grady J, Koengs S, Tamura JK, Woods R, Bansal G, Coughenour D, Tsoa E, Hall WC, Young JF. Development of a heparin-binding F protein mutant of respiratory syncytial virus selectively neutralized in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997, 176:1215-1224.

5. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr., Connor EM, Sondheimer HM: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540.

6. DeVincenzo JP, Hall CB, Kimberlin DW, Sanchez PJ, Rodriguez WJ, Megaw AG, Sullender WM: In vitro and in vivo activity against respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J Virol 1995, 69:543-550.

7. Wu SJ, Schmidt A, Beil EJ, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, et al.: Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1992, 73 ( Pt 9):2217-2223.

8. Lopez JA, Bustos R, Orvell C, Berois M, Ariza J, Garcia-Barreno B, Melero JA: Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 1998, 72:6922-6928.

9. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Tanaka US, Meda RR, Koenig S, Young JF, Dillon SB: A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZ19. J Infect Dis 1999, 180:35-40.

10. Crowe JE, Firestone CY, Crim R, Beeler JA, Coelingh KL, Barbas CF, Burton DR, Chanock RM, Murphy BR: Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 1998, 252:373-375.

11. Karron RA, Wright PF, Crowe JE Jr., Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997, 176:1428-1436.

12. Teng MN, Collins PL: Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol 2001, 75:8285-8296.

13. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001, 289:283-296.

14. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

15. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

16. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

17. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

18. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

19. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

20. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

21. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

22. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

23. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

24. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

25. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

26. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

27. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

28. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

29. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

30. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

31. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

32. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

33. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

34. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

35. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

36. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

37. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

38. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

39. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.

40. Teng MN, Whitehead SS, Collins PL: Contribution of the respiratory syncytial virus F glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. J Virol 2001, 75:8285-8296.